Athira Pharma to Present at Upcoming Investor Conferences
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (Athira), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that company management will participate in the following upcoming investor conferences:
– JMP Securities Life Sciences Conference
– Raymond James Human Health Innovation Conference
BOTHELL, Wash., June 09, 2021 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA) (“Athira“), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that company management will participate in the following upcoming investor conferences:
| • | JMP Securities Life Sciences Conference | |
| Format: Fireside chat | ||
| Date: Thursday, June 17, 2021 | ||
| Time: 3:30 PM ET | ||
| • | Raymond James Human Health Innovation Conference | |
| Panel Topic: Neurodegenerative Diseases: New & Improved Therapeutic Targets for Alzheimer's & Parkinson's Disease | ||
| Participant: Mark Litton, Ph.D., MBA, Chief Operating Officer | ||
| Date: Monday, June 21, 2021 | ||
| Time: 1:20 PM ET |
A live webcast of each presentation can be accessed from the Investors section of the Athira website at https://investors.athira.com/news-and-events/events-and-presentations. An archived replay of the webcast will be available for at least 30 days following the event.
For more detail and to register for the events above, please visit https://investors.athira.com/news-and-events/events-and-presentations
About Athira Pharma, Inc.
Athira, headquartered in the Seattle area, is a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration. We aim to provide rapid cognitive improvement and alter the course of neurological diseases with our novel mechanism of action. Athira is currently advancing its lead therapeutic candidate, ATH-1017, a novel small molecule for Alzheimer’s and Parkinson’s dementia. For more information, visit www.athira.com. You can also follow Athira on Facebook, LinkedIn and @athirapharma on Twitter and Instagram.
Investor & Media Contact:
Julie Rathbun
[email protected]
206-769-9219
